Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area

Dewi, Nadia Artha; Yuzawa, Mitsuko; Tochigi, Kasumi; Kawamura, Akira; Mori, Ryusaburo

doi:10.1007/s10384-008-0551-9

Cited by 18 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In MONT BLANC and DENALI, patients in the combination arms received a mean of 1.7-1.9 verteporfin PDT treatments [15,16]. In patients treated with combination therapy, multiple treatments with verteporfin PDT have been associated with reduced VA gains compared with monotherapy and may explain the lower VA results of these previous studies compared with ours [21]. …”

Section: Discussioncontrasting

confidence: 55%

“…During the initial 3 months, BCVA improvements were delayed in the combination therapy group compared with the monotherapy group; however, by month 6, there was no difference between the groups. The slower improvement in BCVA in the combination therapy group may have resulted from hypoperfusion of the choriocapillaris caused by verteporfin PDT [21]. In both treatment groups, reductions in CRT were paralleled by improvements in BCVA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study

Hatz¹,

Schneider

Henrich

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To investigate the injection frequency and visual acuity (VA) outcomes with combination therapy (ranibizumab plus verteporfin photodynamic therapy, PDT) versus monotherapy (ranibizumab). Methods: A total of 40 patients with exudative age-related macular degeneration were randomized 1:1 to ranibizumab 0.3 mg plus single standard verteporfin PDT or ranibizumab 0.3 mg plus sham PDT. Ranibizumab was administered 3 times monthly followed by ‘as needed' to month 12 based on predetermined vision/anatomical criteria. Retreatment rates, VA outcomes and safety were assessed. Results: During months 3-12, combination therapy patients required fewer ranibizumab injections (mean 1.3) compared with monotherapy patients (2.8). Mean VA improved by 9.0 letters with combination therapy versus 7.5 letters in the monotherapy group at month 12. Both treatment regimens were well tolerated. Conclusion: The need for ranibizumab retreatment might be reduced by administering a single verteporfin PDT on the same day as the first ranibizumab injection, without compromising VA outcomes or safety.

show abstract

Section: Discussioncontrasting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study

Hatz¹,

Schneider

Henrich

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Mild choriocapillaris occlusion remained in the irradiated area in eyes that had undergone multiple PDT sessions 12 months after the initial PDT. 23 Hypoxia may accelerate the expression of vascular epithelial growth factor (VEGF). PDT may alter the natural progression of PCV in the narrow sense, causing enlargement or a change to polypoidal CNV as a result of ischemia and increased VEGF expression.…”

Section: Discussionmentioning

confidence: 99%

Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy

2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dewi et al suggest that RPE atrophy is the natural course of CNV development 18 . Unfortunately, due to the absence of pretreatment evaluation of RPE this finding is limited.…”

Section: Discussionmentioning

confidence: 99%

“…We analysed the area of RPE atrophy after 12 months of follow-up. The analysis was done using a method described by Dewi et al using a hyperflorescence area without leak in late phase of florescein angiograms 18 . The measurement was performed using Topcon i-base software (version 3.8.1.)…”

Section: Methodsmentioning

confidence: 99%

Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD

Šín¹,

Chrapek²,

Karhanová³

et al. 2014

BIOMED PAP

View full text Add to dashboard Cite

Aim. To evaluate photodynamic therapy (PDT) combined with the preferential the cyclooxygenase-2 (COX-2) inhibitor, nabumetone in the treatment of the neovascular age-related macular degeneration (ARMD). Methods. A prospective, double-blind, randomized study on 60 patients with subfoveal CNV secondary to ARMD without any previous treatment. Patients were divided into a nabumetone or placebo group. The main endpoints were the change of best-corrected visual acuity (BCVA), central macular thickness (CRT) and number of required PDT treatments. Results. In the nabumetone group, 27 patients (90%) and 28 (93%) in the placebo group completed the follow-up of 12 months. In the nabumetone group, the mean CRT decreased from 332 μm (SD 68 μm) to 220 μm (SD 46 μm). In the placebo group, CRT decreased from 331 μm (SD 72 μm) to 254 μm (SD 61 μm). The mean BCVA was 0.68 log MAR (SD 0.22 log MAR) in the nabumetone group and 0.62 log MAR (SD 0.23 log MAR) in the placebo group at baseline. This stabilised in the placebo group to 0.66 log MAR (SD 0.33) but deteriorated in the nabumetone group to 0.86 logMAR (SD 0.41 log MAR). There was a significant reduction in the number of required PDTs in the nabumetone group, but significant progression of the RPE atrophy area. Conclusion. Combined PDT with oral intake of the COX-2 inhibitor, nabumetone reduced the number of required PDT retreatments, but worsening BCVA caused by macular atrophy progression. Therefore the combination of the PDT with the nabumetone is not recommended.

show abstract

Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area

Abstract: Although the RPE in the irradiated area was preserved, 12 months after PDT, mild choriocapillaris occlusion was detected in the irradiated area in eyes that had undergone multiple PDT sessions.

Cited by 18 publications

References 10 publications

Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study

Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study

Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy

Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD

Contact Info

Product

Resources

About